Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Given the scalability of the platform and the investments we've made, we think we can consistently deliver leverage growth |
| And then during the quarter, it's clear that the G&A line was very well managed |
| We think with our unique platform and competitive strengths, we think folks should expect us to consistently deliver in the high-single-digits on the top line |
| So we think that the market dynamics will remain strong for us on that and we're going to continue our execution path of being that partner of choice and being able to onboard those patients and continue to provide them care |
| Since the merger in August of 2019, the Option Care Health team has consistently delivered solid growth and met or exceeded our commitments to our shareholders |
| And Pito, on the chronic side and some of the therapies that we outlined, we continue to see strong progress from our commercial team |
| It was a great milestone for our procurement team who we think are the best in the business |
| On the Naven standpoint, again continued really great progress from that platform standpoint |
| We also recently announced our multi-year collaboration with Palantir to deploy their artificial intelligence technology across our operations to drive efficiencies and improve the patient experience |
| We believe our integrated international network of state-of-the-art pharmacies and expanded number of infusion suites combined with the clinical know-how and our leading technology platform continues to resonate with the biopharma partners and positions us well to continually expand our portfolio |
| Their focused dedication and collaboration help ensure that we deliver unparalleled care in the comfort and convenience of our patients' homes or in one of our infusion suites |
| We're really excited about some of the efficiencies and effectiveness that that can help to maximize the capacity and the utilization of that workforce to support not only Option Care Health, but other market participants from that platform |
| A question that has been asked before is from a turnover and from that standpoint, just across the board, we have seen a significant improvement really from '22 as we exited '23 around our retention rates and reducing of overall turnover |
| As the old saying goes, you can do well by doing good and we believe that our financial results for 2023 demonstrate that we are doing just that |
| Adjusted EBITDA of $425 million represents 24% growth over 2022 and significantly exceeded the initial expectations we articulated in early 2023 |
| So overall, 2023 was a very productive year, and we expect to continue our track record of leveraged growth into 2024 |
| As disclosed in this morning's press release, we anticipate delivering another year of solid growth for our shareholders |
| So reflecting on 2023, we continue to deliver strong growth, while investing in this unique platform and our capabilities to enable sustainable growth |
| As we outlined in our 2024 guidance this morning, we expect to continue this trend of delivering strong financial performance as we grow and serve more patients |
| And while we're proud of how far we've come, we're equally excited about the road ahead |
| And our track record is one that we're proud of |
| As John mentioned, we're quite encouraged by the solid finish to 2023 |
| We've also driven dramatic improvements in our balance sheet, reduced the leverage profile by more than two-thirds from 6.2x to 1.8x and slashed net interest expense by more than half from $110 million to $51 million |
| Performance was solid across the portfolio and execution in the field was very strong |
| Four years later, we've increased revenue by 50% to $4.3 billion and more than doubled adjusted EBITDA to $425 million |
| So overall we're quite pleased with the top line performance |
| SG&A of $147.8 million actually declined versus Q4 of 2022 and spending leverage improved to 13.1% of revenue, which we believe affirms the scalability of the platform |
| The great thing is the base business we expect based on our guidance to perform very well this year |
| That high-quality clinical knowledge and know-how, the logistics and the national platform in which we can serve patients and that ability now to have an expanded capability set to not only serve patients in the home, but in one of the infusion suites, all puts us in a really strong position to continue to work with biopharma to be a channel partner and to be able to continue to expand our list of limited distribution drugs or expand the list of products that we have within our portfolio |
| John Rademacher Yes, and the only other thing I will add Brian is on the infusion suite side, continued really great progress by the team of opening the new facility |
| Statement |
|---|
| There's also some areas last year where we had some procurement headwinds on some of the nutritional therapies that we support |
| Obviously, down nearly $10 million sequentially in the fourth quarter and down year-over-year |
| So as a category becomes more competitive, typically, there's ASP and AWP pressure over time, it's not overnight, which typically has headwind on our revenue |
| Admittedly, we did move some of the investments, some of the more discretionary investments, new programs earlier in the year as we knew that we had some margin favorability |
| Naturally, the one thing I would say is, look, growth is going to be a little more muted in the first half just given the fact that we did have some of those Makena and Radicava revenue in the first half of the year |
| Listen, as we've talked about -- and we always get challenged a little bit around, hey, 10% labor productivity for these investments seems a little conservative |
| So, this sounds like maybe a little bit less than what you were expecting |
| Hey, I was worried that you were maybe not tired of answering procurement question for me |
| And so it really dissipated throughout Q4 as we had expected |
| With the spending actually coming down versus the prior year |
| It must meet those hurdles on both ends as we're looking at that |
| Nothing comes to market, no new administration method, no filing is hitting that is of a major surprise to us |
| Given the fact that the chronic, as we've talked about consistently, carries a lower gross margin rate, we would expect going forward that there's going to be some mix shift towards that lower chronic therapy profitability profile |
| John Rademacher And Pito, the only thing I'd add is, look, specific on your question around any positives, negatives |
| I know you guys were hesitant to talk about this two months while you were in the midst of getting those benefits |
| Remember, we had a respiratory therapy business that did have some SG&A burden that obviously went away as we rightsized from that |
| Look, I mean, obviously, for competitive purposes, we're going to be reluctant |
| It pretty much dissipated down to nothing by the end of the fourth quarter |
| These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations |
| And so we will never discount the competitive dynamics that we operate within |
Please consider a small donation if you think this website provides you with relevant information